These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25446772)

  • 1. Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates.
    Sukumaran S; Gadkar K; Zhang C; Bhakta S; Liu L; Xu K; Raab H; Yu SF; Mai E; Fourie-O'Donohue A; Kozak KR; Ramanujan S; Junutula JR; Lin K
    Pharm Res; 2015 Jun; 32(6):1884-93. PubMed ID: 25446772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
    Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
    AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
    Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
    Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against
    Deng R; Zhou C; Li D; Cai H; Sukumaran S; Carrasco-Triguero M; Saad O; Nazzal D; Lowe C; Ramanujan S; Kamath AV
    MAbs; 2019; 11(6):1162-1174. PubMed ID: 31219754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.
    Bryant P; Pabst M; Badescu G; Bird M; McDowell W; Jamieson E; Swierkosz J; Jurlewicz K; Tommasi R; Henseleit K; Sheng X; Camper N; Manin A; Kozakowska K; Peciak K; Laurine E; Grygorash R; Kyle A; Morris D; Parekh V; Abhilash A; Choi JW; Edwards J; Frigerio M; Baker MP; Godwin A
    Mol Pharm; 2015 Jun; 12(6):1872-9. PubMed ID: 25894424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total antibody quantification for MMAE-conjugated antibody-drug conjugates: impact of assay format and reagents.
    Kozak KR; Tsai SP; Fourie-O'Donohue A; dela Cruz Chuh J; Roth L; Cook R; Chan E; Chan P; Darwish M; Ohri R; Raab H; Zhang C; Lin K; Wong WL
    Bioconjug Chem; 2013 May; 24(5):772-9. PubMed ID: 23578050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.
    Cilliers C; Guo H; Liao J; Christodolu N; Thurber GM
    AAPS J; 2016 Sep; 18(5):1117-1130. PubMed ID: 27287046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
    Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
    Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates.
    Dennler P; Chiotellis A; Fischer E; Brégeon D; Belmant C; Gauthier L; Lhospice F; Romagne F; Schibli R
    Bioconjug Chem; 2014 Mar; 25(3):569-78. PubMed ID: 24483299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Conjugation Site and Technique on the Stability and Pharmacokinetics of Antibody-Drug Conjugates.
    Kaempffe A; Dickgiesser S; Rasche N; Paoletti A; Bertotti E; De Salve I; Sirtori FR; Kellner R; Könning D; Hecht S; Anderl J; Kolmar H; Schröter C
    J Pharm Sci; 2021 Dec; 110(12):3776-3785. PubMed ID: 34363839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model.
    Wang-Lin SX; Zhou C; Kamath AV; Hong K; Koppada N; Saad OM; Carrasco-Triguero M; Khojasteh C; Deng R
    MAbs; 2018 Oct; 10(7):1131-1143. PubMed ID: 30081725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
    Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration.
    Chan LJ; Bulitta JB; Ascher DB; Haynes JM; McLeod VM; Porter CJ; Williams CC; Kaminskas LM
    Mol Pharm; 2015 Mar; 12(3):794-809. PubMed ID: 25644368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody-drug Conjugate (ARX788) for Breast Cancer Treatment.
    Nagaraja Shastri P; Zhu J; Skidmore L; Liang X; Ji Y; Gu Y; Tian F; Yao S; Xia G
    Mol Cancer Ther; 2020 Sep; 19(9):1822-1832. PubMed ID: 32499302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.
    Pouzin C; Gibiansky L; Fagniez N; Chadjaa M; Tod M; Nguyen L
    J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):381-394. PubMed ID: 35166967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-Specific Conjugation to Cys-Engineered THIOMAB™ Antibodies.
    Adhikari P; Zacharias N; Ohri R; Sadowsky J
    Methods Mol Biol; 2020; 2078():51-69. PubMed ID: 31643049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios.
    Clardy SM; Uttard A; Du B; Catcott KC; Lancaster KL; Ditty E; Sadowsky J; Zurita J; Malli N; Qin L; Bradley SP; Avocetien K; Carter T; Kim D; Nazzaro M; Xu L; Pillow TH; Zacharias NT; Lewis GD; Rowntree RK; Iyengar R; Lee DH; Damelin M; Toader D; Lowinger TB
    Mol Cancer Ther; 2024 Jan; 23(1):84-91. PubMed ID: 37774393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.